CCTV+
10.12.2020 10:32:09 CET | Business Wire | Press release
A statement on strengthening media cooperation issued by China Media Group (CMG) and its European media partners, calling on the Chinese and European media to fulfill their responsibilities as public information disseminators and jointly help the international community to gather a strong force to overcome the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005312/en/
CMG and its European media partners issued the statement. /CCTV+
The statement was made during the “2020 European Media Partners Cooperation Online Forum” on December 10, hosted by CMG with the theme of “Mutual Trust Dialogue for Win-Win Cooperation”.
Twenty-eight delegates from 25 organizations in 16 European countries and China had in-depth discussions on how to strengthen coordination, deepen ties, unite to fight the pandemic, and bring greater confidence to the world through in-depth exchanges.
CMG’s President and Editor-in-Chief, Shen Haixiong put forward three proposals on the current media situation. He said, “First, we should deepen cooperation in reporting COVID-19 responses; Second, we should promote the exchange of personnel between the media organizations; Third, we should strengthen the construction of our cooperation mechanism.”
In his speech, he pointed out, China and Europe share a broad consensus and common interests in supporting and practicing multilateralism, strengthening the global response to COVID-19, and jointly promoting global economic recovery and addressing the issue of climate change. We share far more consensus than divergences. Chinese and European media partners will also move towards a new stage of closer, deeper, and more pragmatic dialogue, exchange and cooperation.
Michael Friedenberg, the President of Reuters, said, “We must recognize the power of partnerships in this new media ecosystem. This can take the form of collaborative journalism, industry coalitions, new commercial business opportunities, content-sharing or shared platforms.”
He also mentioned CMG and CCTV+ are important partners and our partnership continues to be a priority.
“Without a clear two-way information communication, there will never be full trust and in-depth cooperation. Therefore, in a friendly relation between different countries and peoples, the media plays a vital role,” said Paolo Panerai, the Editor-in-Chief & CEO of Class Editori S.p.A.’s.
“As global interdependence grows, I believe that media companies cannot work in silos anymore,” Michael Peters, CEO and President of Executive Board of Euronews emphasized. He believes that Euronews and CMG will continue to deepen our collaboration in fostering a better understanding between our cultures.
A launch ceremony of China Business Video (CBV) was also held between CCTV+ and Reuters. It provides Reuters’ customers with financial news content from China, which will be distributed straight by CMG to improve media cooperation between China and other media and to strengthen information exchanges.
At the forum, Teng Yunping, President of CCTV Video News Agency (CCTV+), and Adrian Wells, Managing Director of European News Exchange (ENEX) signed a Strategic Memorandum of Understanding , which signals the official launch of the “European Media Partners (EMP)”. In the future, the two sides will strengthen cooperation on news materials, news reports, overseas reporters, news products, and media forums.
At the same time, the program, BizToday , was released to provide “European Media Partners” with tailored Chinese and European financial news jointly created by CMG, CCTV+ and ENEX.
During the forum, representatives from China and Europe joined an online panel discussion with the theme “Multilateral Cooperation and Mutual Trust, Common Challenges and Win-Win Future” to discuss how the Chinese and European media promote mutual trust between people from both sides and carry out multilateral cooperation to achieve win-win results.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005312/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom